Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 10;9(5):478-483.
doi: 10.1021/acsmedchemlett.8b00092. eCollection 2018 May 10.

Structure-Activity Relationships of Radioiodinated Benzoimidazopyridine Derivatives for Detection of Tau Pathology

Affiliations

Structure-Activity Relationships of Radioiodinated Benzoimidazopyridine Derivatives for Detection of Tau Pathology

Sho Kaide et al. ACS Med Chem Lett. .

Abstract

It is generally accepted that neurofibrillary tangles consisting of tau proteins are involved in the pathogenesis of Alzheimer's disease (AD). For selective detection of tau pathology, we synthesized and evaluated radioiodinated benzoimidazopyridine (BIP) derivatives with an alkylamino group as tau imaging probes. In vitro selectivity to tau aggregates and in vivo pharmacokinetics of BIP derivatives varied markedly, being strongly dependent on the alkylamino group. In in vitro autoradiography with AD brain sections, the BIP derivative with a dimethylamino group (BIP-NMe2) showed the highest selectivity to tau aggregates. Regarding the biodistribution using normal mice, the BIP derivative with an ethylamino group (BIP-NHEt) showed the highest uptake (6.04% ID/g at 2 min postinjection) into and rapid washout (0.12% ID/g at 60 min postinjection) from the brain. These results suggest that the introduction of an optimal alkylamino group into the BIP scaffold may lead to the development of more potential tau imaging probes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
125I-labeled BIP derivatives reported as tau imaging probes.
Scheme 1
Scheme 1
Reagent and conditions: (a) Boc2O, DMAP, Et3N, THF, 80 °C; (b) 2,5-dibromoaniline, CuI(I), 1,10-phenanthroline, Cs2CO3, xylene, 120 °C; (c) (SnBu3)2, Pd(PPh3)4, Et3N, dioxane, 95 °C; (d) I2, CHCl3, rt; (e) TFA, CH2Cl2, rt; (f) CH3I, NaH, 0 °C; (g) CH3CH2I, NaH, 0 °C; (h) CH3CH2CH2I, NaH, 0 °C.
Scheme 2
Scheme 2
Reagent and conditions: (a) (1) [125I]NaI, H2O2, 1 N HCl, rt; (2) TFA, CHCl3; (b) [125I]NaI, H2O2, 1 N HCl, rt.
Figure 2
Figure 2
Comparison of in vitro autoradiograms with 125I-labeled BIP derivatives in AD brain sections from the frontal (A) and temporal (B) lobes.
Figure 3
Figure 3
Quantitative analysis of in vitro autoradiography with AD brain sections. Data are presented as the mean ± SEM (n = 3–4).
Figure 4
Figure 4
Comparison of uptake into and clearance from the brain after the intravenous injection of 125I-labeled BIP derivatives into normal mice (n = 5). aData were reported previously.

Similar articles

Cited by

References

    1. Citron M. Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discovery 2010, 9, 387–398. 10.1038/nrd2896. - DOI - PubMed
    1. Du X.; Wang X.; Geng M. Alzheimer’s disease hypothesis and related therapies. Transl. Neurodegener. 2018, 7, 2.10.1186/s40035-018-0107-y. - DOI - PMC - PubMed
    1. Serrano-Pozo A.; Frosch M. P.; Masliah E.; Hyman B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspect. Med. 2011, 1, a006189.10.1101/cshperspect.a006189. - DOI - PMC - PubMed
    1. Svedberg M. M.; Rahman O.; Hall H. Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer’s disease. Nucl. Med. Biol. 2012, 39, 484–501. 10.1016/j.nucmedbio.2011.10.007. - DOI - PubMed
    1. Rowe C. C.; Ng S.; Ackermann U.; Gong S. J.; Pike K.; Savage G.; Cowie T. F.; Dickinson K. L.; Maruff P.; Darby D.; Smith C.; Woodward M.; Merory J.; Tochon-Danguy H.; O’Keefe G.; Klunk W. E.; Mathis C. A.; Price J. C.; Masters C. L.; Villemagne V. L. Imaging β-amyloid burden in aging and dementia. Neurology 2007, 68, 1718–1725. 10.1212/01.wnl.0000261919.22630.ea. - DOI - PubMed